Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation

被引:17
作者
Bastianelli, Carlo [1 ]
Farris, Manuela [2 ]
Rosato, Elena [1 ]
Brosens, Ivo [3 ]
Benagiano, Giuseppe [1 ]
机构
[1] Sapienza Univ Rome, Dept Gynecol Obstet & Urol, Rome, Italy
[2] AIED, Rome, Italy
[3] Katholieke Univ Leuven, Fac Med, Leuven, Belgium
关键词
Androgens; combined oral contraceptives; drospirenone; estradiol; estradiol valerate; estrogens; ethinyl estradiol; hemostasis; nomegestrol acetate; progestins; PITUITARY-OVARIAN FUNCTION; HORMONE-FREE INTERVAL; G ETHINYL ESTRADIOL; PILL-FREE INTERVAL; MU-G; NOMEGESTROL ACETATE; 19-NOR STEROIDS; ANTIGONADOTROPIC ACTIVITY; CHLORMADINONE ACETATE; DESOGESTREL;
D O I
10.1080/17512433.2018.1536544
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Following a historical overview, the ovulation-inhibiting effect of various orally administered estrogen-progestin combinations (combined oral contraceptives [COCs]) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Inhibition of ovulation with progestins alone; estrogens alone; various progestins in combination with ethinyl estradiol; various progestins in combination with natural estrogens (estradiol, estradiol valerate, and estetrol). Expert commentary: The original idea to achieve ovulation blockage through the administration of steroid hormones involved the use a progestogen (both progesterone and its synthetic homologous). The ability of a progestin to inhibit ovulation depends on the type of compound and on its dosage and a difference of more than 20-fold in activity exists between compounds utilized today in COCs. Initially, the estrogenic component was present only because it contaminated the first progestin utilized. It was soon found that an estrogen is necessary for proper cycle control. It was also found that the estrogen acts synergistically in inhibiting ovulation. For almost half a century, most COCs contained ethinyl estradiol. Today, also natural estrogens are being employed. Inhibition of ovulation was complete with all early high dose preparations. Decreasing dosage allowed some ovarian activity to occur, occasionally leading to a mature follicle. Even in this situation, defective corpus luteum formation assured contraceptive protection.
引用
收藏
页码:1085 / 1098
页数:14
相关论文
共 126 条
  • [21] Diczfalusy E, 1983, PROGESTOGENS THERAPY, P133
  • [22] Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study
    Duijkers, Ingrid J. M.
    Klipping, Christine
    Zimmerman, Yvette
    Appels, Nicole
    Jost, Maud
    Maillard, Catherine
    Mawet, Marie
    Foidart, Jean-Michel
    Bennink, Herjan J. T. Coelingh
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2015, 20 (06) : 476 - 489
  • [23] Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol
    Duijkers, Ingrid J. M.
    Klipping, Christine
    Grob, Paul
    Korver, Tjeerd
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2010, 15 (05) : 314 - 325
  • [24] OVARIAN-FUNCTION DURING LOW-DOSE ORAL-CONTRACEPTIVE USE
    EGARTER, C
    PUTZ, M
    STROHMER, H
    SPEISER, P
    WENZL, R
    HUBER, J
    [J]. CONTRACEPTION, 1995, 51 (06) : 329 - 333
  • [25] Conception and pharmacodynamic profile of drospirenone
    Elger, W
    Beier, S
    Pollow, K
    Garfield, R
    Shi, SQ
    Hillisch, A
    [J]. STEROIDS, 2003, 68 (10-13) : 891 - 905
  • [26] Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment
    Elomaa, K
    Lähteenmäki, P
    [J]. CONTRACEPTION, 1999, 60 (05) : 275 - 279
  • [27] Elstein M, 1969, CHLORMADINONE ACETAT, P46
  • [28] Plasma concentrations of endogenous hormones during one regular treatment cycle with a low-dose oral contraceptive and during two cycles with deliberate omission of two tablets
    Endrikat, J
    Wessel, J
    Rosenbaum, P
    Düsterberg, B
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2004, 18 (06) : 318 - 326
  • [29] Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies
    Endrikat, Jan
    Parke, Susanne
    Trummer, Dietmar
    Schmidt, Werner
    Duijkers, Ingrid
    Klipping, Christine
    [J]. CONTRACEPTION, 2008, 78 (03) : 218 - 225
  • [30] Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study
    Endrikat, Jan
    Parke, Susanne
    Trummer, Dietmar
    Serrani, Marco
    Duijkers, Ingrid
    Klipping, Christine
    [J]. CONTRACEPTION, 2013, 87 (02) : 227 - 234